NIAGEN BIOSCIENCE, INC. (NAGE) filed an 8-K on November 4, 2025, disclosing strong financial results for the quarter ended September 30, 2025, alongside strategic updates.
Q3 2025 Financial Highlights: Net Sales reached $34.0 million, marking a 33% year-over-year increase, driven by Tru Niagen® sales which grew 44% to $26.0 million (77% of total revenue). Profitability improved substantially, with Net Income of $4.6 million ($0.06 EPS) and Adjusted EBITDA surging 120% to $6.4 million. Gross Margin rose 100 basis points to 64.5%. The company maintained strong liquidity, ending the qua
...